Company intelligence / Profile preview
LaunXP Biomedical Co., Ltd.
Taipei / Taichung City, Taiwanlaunxp.com ↗
- Ownership
- Public · 6876
- Employees
- ~26
- Development stage
- Phase 1
01
Overview
LaunXP Biomedical is advancing a pipeline of novel small molecule and biologic drug candidates for oncology and neurodegenerative diseases. Its lead asset, LXPB‑5268 for triple negative breast cancer, is in Phase 2 clinical trials. Other programs are in preclinical or early clinical stages targeting solid tumors, AML, NSCLC, pancreatic cancer, and Alzheimer’s disease. No late-stage or commercialized products as of May 2025.[4][5]
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small molecules (new chemical entities, kinase inhibitors)Virus-like particles[5][7][9]
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Financials
- Market cap
- $26.7M
- Total revenue
- $0
- Enterprise value
- $13.1M
Beyond the preview
Go deeper on LaunXP Biomedical Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LaunXP Biomedical Co., Ltd..